TP53 and breast carcinoma: In a meta-analysis of ~2500 patients across 44 studies focused on MENA breast cancer patients, TP53 mutations (≈23.8%) and PIK3CA mutations (≈10.2%) emerged as the most frequent somatic alterations, followed by ~mutations in BRCA1/2, ATM, ESR1, and PTEN [16].